Clinical trials: Fibrosis and Cirrhosis of Liver
Chronic Hepatitis B
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy.
- Trial name
- NCT03366571
- Testing
- Nucleos(t)ide Analogues
- Where
- 4 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Artificial Intelligence
AI-assisted Gastroscopic Varicose Vein Diagnosis
Validation of the accuracy of AI in assisting gastroscopic varices diagnosis through a prospective multicenter study
- Trial name
- NCT05293457
- Where
- China
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
Hepatocellular Carcinoma, Cirrhosis, Liver
Liver Cancer Disparities in American Indian and Alaska Native Persons
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B
- Trial name
- NCT05304234
- Testing
- Ultrasound or abbreviated MRI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Washington
Primary Biliary Cholangitis
Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
This is an observational, retrospective cohort study of patients with primary biliary cholangitis (PBC) who failed ursodeoxycholic acid (UDCA) treatment, using a real-world data source, the Komodo Health United States (US) claims…
- Trial name
- HEROES PBC (NCT05292872)
- Where
- United States
- Volunteers
- 4,577 people
- Sponsor
- Intercept Pharmaceuticals
Liver Fibrosis
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Patients with chronic hepatitis B histologically confirmed of liver fibrosis S2/S3 (similar to metavir F2/F3, Ishak 2/3/4) are randomly assigned in a 1:1 ratio.
- Trial name
- NCT01938781
- Testing
- entecavir, Peg-IFN
- Where
- 21 sites in China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Cirrhosis
Insertion Technique in Large Volume Paracentesis
The purpose of this study is to compare two different methods that are used for inserting the needle during paracentesis. One method is called the "coaxial insertion technique" and the other is called the "z-tract technique".
- Trial name
- NCT02310165
- Testing
- Z-tract Insertion Technique, Coaxial Insertion Technique
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Virginia
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Wilsons Disease
sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis
The aim is to investigate macrophage activation markers and correlations to liver fibrosis in patients with Wilsons Disease. Researchers wish to investigate associations to neurologic and metabolic liver function.
- Trial name
- NCT02702765
- Testing
- Fibroscan, Ultrasound, Galactose
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- University of Aarhus
Primary Biliary Cholangitis
Clinical Study on the Treatment of Elevated Total Bilirubin in Primary Biliary Cholangitis With Baobao Dan Capsule
1. Explore the effect of Babaodan Capsule on the serum total bilirubin level of primary biliary cholangitis patients with elevated total serum bilirubin; 2.
- Trial name
- NCT06371196
- Testing
- Babaodan Capsule
- Volunteers
- 60 people
- Sponsor
- Mei Han
Liver Cirrhosis
Human Fetal Liver Cell Transplantation in Chronic Liver Failure
The herein study consists in the transplantation of liver progenitor cells isolated from human fetal liver tissue with the aim of improving conventional liver therapy and broadening therapeutical options other than liver…
- Trial name
- hFLCTx (NCT01013194)
- Testing
- Human Fetal Liver Cell Transplantation
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Cirrhosis, Liver, Gastroesophageal Varices
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
The goal of this research is to validate novel non-invasive Magnetic resonance imaging (MRI) biomarkers to detect Gastroesophageal varices (GEV) in patients with cirrhosis, including fractional flow change in the portal vein and…
- Conditions
- Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
- Trial name
- NCT04867954
- Testing
- Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Liver Cirrhosis, Portal Vein Thrombosis
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
- Trial name
- NCT04173429
- Testing
- Nadroparin calcium, warfarin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Qilu Hospital of Shandong University
Decompensated Cirrhosis, Portal Hypertension
The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure.
- Conditions
- Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices, Refractory Ascites
- Trial name
- NCT01440829
- Testing
- L-ornithine-L-aspartate
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Air Force Military Medical University, China
Hepatic Encephalopathy, Minimal Hepatic Encephalopathy
Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
Patients with cirrhosis of the liver may suffer from a condition called hepatic encephalopathy which in its mildest form as mental slowing and impaired reaction times in driving and machinery operation.
- Conditions
- Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Cirrhosis
- Trial name
- NCT01847651
- Testing
- Vastus Muscle Biopsy, Cognitive assessment (PHES), Cognitive Assessement (Cogstate)
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to changes in economic conditions and lifestyle, and it is anticipated to become a significant liver disease burden in the…
- Trial name
- NCT06762223
- Testing
- Henagliflozin 10 mg daily, Metformin 1700 mg daily
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Xiqiao Zhou
Portal Hypertension, Chronic Liver Disease
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
This prospective multicentre observational reliability study will determine how much a repeated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement differs from the first measurement in the same patient…
- Conditions
- Portal Hypertension, Chronic Liver Disease, Liver Cirrhosis
- Trial name
- REPEAT-PPG (NCT07877298)
- Testing
- Repeated EUS-Guided Portal Pressure Gradient Measurement
- Where
- 5 sites in Belgium, Canada and 2 more
- Volunteers
- 150 people
- Sponsor
- University Hospital Muenster
Portal Hypertension, Cirrhosis
WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis
Portal hypertension is a common complication of chronic liver diseases and is responsible for most clinical consequences of cirrhosis.
- Trial name
- NCT03195634
- Testing
- Carvedilol
- Volunteers
- 80 people
- Sponsor
- Shanghai Changzheng Hospital
Biliary Stricture, Bile Duct Stenosi
Biliary Complications in Live Donor Liver Transplantation
The study was designed as a prospective cohort study. The effects of hot and cold ischemic times during live donor liver transplantation on postoperative 1-3 and 6 month follow up biliary complications will be investigated.
- Conditions
- Biliary Stricture, Bile Duct Stenosi, Bile Leak, Bile Duct Injury
- Trial name
- NCT03673033
- Testing
- liver transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Inonu University
Primary Biliary Cholangitis (PBC)
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response…
- Trial name
- NCT03124108
- Testing
- Elafibranor 80 mg, Elafibranor 120 mg
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 45 people
- Sponsor
- Genfit